Copyright: ©Author(s) 2026.
World J Orthop. Mar 18, 2026; 17(3): 115155
Published online Mar 18, 2026. doi: 10.5312/wjo.v17.i3.115155
Published online Mar 18, 2026. doi: 10.5312/wjo.v17.i3.115155
Table 2 Comparison of the number and grading of toxic side effects during chemotherapy between the locomotive syndrome group and the non-locomotive syndrome group, n (%)
| Group | n | Toxic side effects (mean ± SD) | Grading of toxic side effects | ||||
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |||
| LS group | 161 | 16.1 ± 3.8 | 27 (16.7) | 36 (22.4) | 38 (23.6) | 36 (22.4) | 24 (14.9) |
| Non-LS group | 225 | 11.3 ± 4.1 | 52 (23.1) | 68 (30.3) | 75 (33.3) | 20 (8.9) | 10 (4.4) |
| t/Z | 14.127 | 3.234 | |||||
| P value | < 0.001 | 0.006 | |||||
- Citation: Liang DH, Feng XR, Li L, Chen Y, Yang YL. Impact of pre-chemotherapy locomotive syndrome status on short-term adverse outcome events in elderly lung cancer patients: A longitudinal study. World J Orthop 2026; 17(3): 115155
- URL: https://www.wjgnet.com/2218-5836/full/v17/i3/115155.htm
- DOI: https://dx.doi.org/10.5312/wjo.v17.i3.115155